Bioinformatics Approaches to Predict Drug Responses from Genomic Sequencing.
暂无分享,去创建一个
[1] J. Larkin,et al. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. , 2012, Future oncology.
[2] D. Botstein,et al. A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.
[3] S. Chanock,et al. Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data. , 2014, Cancer research.
[4] W. Huber,et al. which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .
[5] M. McCarthy,et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges , 2008, Nature Reviews Genetics.
[6] Manuel Hidalgo,et al. Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. , 2008, Cancer research.
[7] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[8] Thomas Lengauer,et al. A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.
[9] Helga Thorvaldsdóttir,et al. Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..
[10] J. Briones. Emerging therapies for B-cell non-Hodgkin lymphoma , 2009, Expert review of anticancer therapy.
[11] R. Shoemaker. The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.
[12] Eytan Ruppin,et al. Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality , 2014, Cell.
[13] A. Giaccia,et al. Harnessing synthetic lethal interactions in anticancer drug discovery , 2011, Nature Reviews Drug Discovery.
[14] L. Staudt,et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling , 2005 .
[15] Chartchalerm Isarankura-Na-Ayudhya,et al. Advances in computational methods to predict the biological activity of compounds , 2010, Expert opinion on drug discovery.
[16] C. Ting,et al. A genome-wide association study identifies new loci for ACE activity: potential implications for response to ACE inhibitor , 2010, The Pharmacogenomics Journal.
[17] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[18] L. Samson,et al. Genomic predictors of interindividual differences in response to DNA damaging agents. , 2008, Genes & development.
[19] Nan Song,et al. Analysis of chemotherapeutic response heterogeneity and drug clustering based on mechanism of action using an in vitro assay. , 2010, Anticancer research.
[20] Neel Madhukar,et al. Abstract B162: Small molecule target prediction and identification of novel anti-cancer compounds using a data-driven bayesian approach , 2015 .
[21] Xiaomin Luo,et al. TarFisDock: a web server for identifying drug targets with docking approach , 2006, Nucleic Acids Res..
[22] Simon C. Potter,et al. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.
[23] Matthew R. Laird,et al. Protein Protein Interaction Network Evaluation for Identifying Potential Drug Targets , 2009 .
[24] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[25] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[26] Wentian Li,et al. Genome-Wide Association Scan Identifies Candidate Polymorphisms Associated with Differential Response to Anti-TNF Treatment in Rheumatoid Arthritis , 2008, Molecular medicine.
[27] F. Cappuzzo,et al. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. , 2006, The New England journal of medicine.
[28] P. Hirth,et al. Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.
[29] Henning Hermjakob,et al. The Reactome pathway Knowledgebase , 2015, Nucleic acids research.
[30] David R. Kelley,et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.
[31] Mathias Wilhelm,et al. Global proteome analysis of the NCI-60 cell line panel. , 2013, Cell reports.
[32] Jason H. Moore,et al. Chapter 11: Genome-Wide Association Studies , 2012, PLoS Comput. Biol..
[33] Yudong D. He,et al. Functional Discovery via a Compendium of Expression Profiles , 2000, Cell.
[34] R. Collins,et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.
[35] Nicholas M. Pajewski,et al. Six Degrees of Epistasis: Statistical Network Models for GWAS , 2011, Front. Gene..
[36] Karin Breuer,et al. InnateDB: systems biology of innate immunity and beyond—recent updates and continuing curation , 2012, Nucleic Acids Res..
[37] C. Orengo,et al. Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma , 2006, BMC Genomics.
[38] Lin He,et al. Prediction of Drug-Target Interactions for Drug Repositioning Only Based on Genomic Expression Similarity , 2013, PLoS Comput. Biol..
[39] E. Pearson,et al. Insights from genome-wide association studies of drug response. , 2013, Annual review of pharmacology and toxicology.
[40] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[41] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Susumu Goto,et al. KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..
[43] J. Marchini,et al. Genotype Imputation with Thousands of Genomes , 2011, G3: Genes | Genomes | Genetics.
[44] D. Butina,et al. Predicting ADME properties in silico: methods and models. , 2002, Drug discovery today.
[45] Pablo Villoslada,et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. , 2008, Archives of neurology.
[46] M. Ashburner,et al. Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.
[47] M. Eileen Dolan,et al. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci , 2010, Proceedings of the National Academy of Sciences.
[48] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[49] Mary Regina Boland,et al. A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors. , 2016, Cell reports.
[50] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[51] Michiaki Kubo,et al. Genome-Wide Association Study: A Useful Tool to Identify Common Genetic Variants Associated with Drug Toxicity and Efficacy in Cancer Pharmacogenomics , 2014, Clinical Cancer Research.
[52] P. Bork,et al. Drug Target Identification Using Side-Effect Similarity , 2008, Science.
[53] Jack A. Taylor,et al. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies , 2009, Nucleic Acids Res..
[54] Julio Saez-Rodriguez,et al. Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties , 2012, PloS one.
[55] Ellen T. Gelfand,et al. The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.
[56] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[57] P. Meltzer,et al. NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses , 2014, PloS one.
[58] Justin Lamb,et al. The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.
[59] P. Meltzer,et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. , 2013, Cancer research.
[60] Olivier Elemento,et al. A primer on precision medicine informatics , 2016, Briefings Bioinform..
[61] Michael P. Morrissey,et al. Pharmacogenomic agreement between two cancer cell line data sets , 2015, Nature.
[62] Adrian Wiestner,et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[63] Nci Dream Community. A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .
[64] Joel Dudley,et al. Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..
[65] A. Weeraratna,et al. Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells , 2007, Oncogene.
[66] B. Leber,et al. Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells , 2012, Cell.
[67] Gaurav Pandey,et al. Prediction of Genetic Interactions Using Machine Learning and Network Properties , 2015, Front. Bioeng. Biotechnol..
[68] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[69] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[70] Manuel A. R. Ferreira,et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.